Yale Medicine Surgeons Use 3D Printing to Benefit Patients
Some Yale Medicine surgeons now routinely use 3D printing (essentially producing a solid, three-dimensional object from a virtual digital model) to plan surgeries, design tools specific to an upcoming surgery and that particular patient’s anatomy, and even to print some of the parts used to replace defective ones in the body.Source: Yale Medicine
Dr. Raul Guzman to Lead Vascular Surgery
Dr. Raul Guzman will be joining the team as Division Chief of Vascular Surgery, effective June 3, 2019. Additionally, Dr. Guzman will be appointed as Surgeon-in-Chief, Vascular Surgery, Heart and Vascular Center for the Yale New Haven Health System, and Chief of Vascular Surgery at Yale New Haven Hospital.
Dr. Mulligan Elected President of OPTN/UNOS
Dr. David Mulligan, Chief of Transplantation, Department of Surgery, has been elected Vice President, President-Elect of the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Board of Directors. The OPTN/UNOS manages the nation’s organ transplant network under federal contract.
Taking the Embarrassment Out of Health Problems
We humans seem to have a nearly universal need to avoid embarrassment. It could be something as simple as mispronouncing a word or tripping as you walk along a crowded sidewalk. No matter the blunder, our response is instinctive: Hide, hope no one noticed and move on. But what happens when what you are embarrassed about is related to your health? There are some aspects of your body and how it functions that you'd really rather not talk about—even with a doctor. But sharing potentially embarrassing symptoms with your physicians may be the only way for them to accurately diagnose and treat you. Chances are specialists have heard it—and seen it—all before and know how to help.
Zimbrean paper: Altruistic, non-directed kidney donors should receive psychiatric assessment
Paula Zimbrean, MD, FAPA, Associate Professor of Psychiatry and Director of Transplant Psychiatry Services at Yale New Haven Hospital, is the senior author of a paper published in the Journal of Psychosomatic Research that reflects an expert consensus on the psychiatric assessment of altruistic non-directed kidney donors.
Free head and neck screenings at Yale New Haven Hospital
More than 50,000 people in the U.S. are diagnosed with head and neck cancer every year. Free screenings are available at Yale New Haven Hospital to bring awareness and prevention. Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center will hold a free oral, head and neck cancer screening on Friday, May 11 from 3 - 6:30 pm in the East Pavilion.Source: WTNH
Breast cancer screening linked to lower stage at diagnosis, less intensive treatment
Patients who underwent breast cancer screening appeared to be diagnosed at an earlier stage and underwent less extensive medical and surgical treatment, according to a study presented at The American Society of Breast Surgeons Annual Meeting. This association persisted among patients aged 40 to 49 years, for whom controversy exists on the necessity of screening.Source: Healio
Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'
Connecticut Magazine has named 77 Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven physicians and surgeons to its 2018 Best Doctors guide. Published in the magazine's April issue, the Best Doctors list consists of 779 Connecticut physicians from 78 medical specialties.
Trumbull medical center adds multidisciplinary Head and Neck Cancer Clinic
Smilow Cancer Hospital has opened a multidisciplinary head and neck cancer clinic, the first of its kind in Fairfield County, at Yale New Haven Health’s Park Avenue Medical Center in Trumbull. The clinic coordinates and streamlines care for the convenience of patients, according to Dr. Heather Osborn. A Yale Medicine head and neck surgeon, Osborn is teaming with radiation oncologist Dr. Kirtesh Patel and medical oncologist Dr. Harold Tara to create a personalized treatment plan for each patient.Source: Westfair Communications
Avoiding Unnecessary Surgery and Radiation in Low-Risk DCIS
The routine use of screening mammography has drastically increased the identification of ductal carcinoma in situ (DCIS) over the past 3 decades. However, results from current research suggest that many cases of DCIS have a low risk for progression and thus may not require surgical excision and radiation therapy. Although early detection of DCIS enables patients to receive treatment before the cancer becomes invasive, Anees B. Chagpar, MD, MSc, MPH, MA, MBA, pointed out that some patients are treated for low-grade precancerous lesions that probably would not develop into invasive cancers or affect longevity. “If they had never known about those lesions, they could have just as well lived their life,” said Chagpar, associate professor in the Department of Surgery at the Yale School of Medicine and the assistant director for global oncology at the Yale Comprehensive Cancer Center. “Now they are undergoing all kinds of treatments for these lesions, and is that really necessary?”Source: OncLive
Many Women Misjudge How They'll Feel After Mastectomy
Women who have one or both breasts removed to treat cancer may have unrealistic expectations about how they’ll feel after that surgery and after breast reconstruction, if they choose that option, a U.S. study suggests. For the study, researchers surveyed 96 women with breast cancer before they had a mastectomy and again one year later. The study included 42 women who had breast reconstruction surgery right after the mastectomy. Overall, patients who had a mastectomy without reconstruction significantly underestimated how satisfied they would be with their breasts and their quality of life afterwards, researchers report in JAMA Surgery.Source: Newsmax
Yale’s advance in breast cancer surgery to be tested in nationwide study
Removing a small amount of extra tissue around a breast cancer tumor may keep a patient from having a recurrence of the cancer or of having to return to the operating table because not all of the malignant cells were removed in the first operation. That’s the theory that’s being tested in a nationwide clinical trial sponsored by the Yale Cancer Center called SHAVE2. Dr. Anees Chagpar, assistant director of global oncology at the Yale School of Medicine and former director of the Breast Center, is the principal investigator. Chagpar oversaw the first SHAVE trial at Yale, which involved 235 patients with stage 0 to stage 3 breast cancer who were given a partial mastectomy, also known as a lumpectomy. Some were given normal lumpectomies, while others had more tissue removed from around the tumor site, known as cavity shave margins.Source: New Haven Register